The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The nerve cells need glutamate receptors – think of them ... insurance will cover is the FDA-approved nasal spray esketamine (Spravato). Because the FDA hasn't approved IV ketamine for ...

This quick onset provides hope to patients who may have struggled with depression for years. Moreover, Spravato’s mechanism, targeting glutamate pathways to promote brain connectivity and healing, ...

This quick onset provides hope to patients who may have struggled with depression for years. Moreover, Spravato’s mechanism, targeting glutamate pathways to promote brain connectivity and healing, ...

According to J&J, Spravato is an N-methyl-D-aspartate (NMDA) receptor antagonist that appears to work by acting on a pathway in the brain that affects glutamate — a neurotransmitter that helps ...

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate use of ...

Esketamine has been shown to affect glutamate signaling in a matter of days, while oral antidepressants can take weeks. Spravato isn’t like the nasal spray you use when you have a cold.